CRNX

insider transactions

Crinetics Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-136.2K

0 buy · 136.2K sell

Net value · 365d

-$5.1M

$0 in · $5.1M out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 136.2K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Sell·S
Mar 16, 26

Betz Stephen F.

Chief Scientific Officer · 10b5-1

$160.2K

4.2K sh · $37.77

Own -3%
Sell·S
Mar 16, 26

Betz Stephen F.

Chief Scientific Officer · 10b5-1

$236.4K

6.4K sh · $37.11

Own -4%
Sell·S
Mar 16, 26

Struthers Richard Scott KEY

President & CEO · 10b5-1

$331.8K

8.8K sh · $37.77

Own -2%
Sell·S
Mar 16, 26

Struthers Richard Scott KEY

President & CEO · 10b5-1

$489.7K

13.2K sh · $37.11

Own -3%
Sell·S
Mar 16, 26

Knight Jeff E.

Chief Operating Officer · 10b5-1

$220.8K

6.0K sh · $37.11

Own -5%
Sell·S
Mar 16, 26

Knight Jeff E.

Chief Operating Officer · 10b5-1

$149.6K

4.0K sh · $37.77

Own -3%
Sell·S
Mar 12, 26

Vivaldi Coelho Rogerio

Director · 10b5-1

$19.2K

523 sh · $36.77

Own -3%
Sell·S
Mar 12, 26

Vivaldi Coelho Rogerio

Director · 10b5-1

$161.5K

4.5K sh · $36.08

Own -21%
Sell·S
Mar 3, 26

Okey Stephanie

Director · 10b5-1

$119.0K

3.0K sh · $39.67

Own -18%
Sell·S
Mar 3, 26

Schilke Tobin KEY

Chief Financial Officer · 10b5-1

$266.3K

6.7K sh · $39.67

Own -8%
Grant·A
Feb 23, 26

Struthers Richard Scott KEY

President & CEO

$0

228.0K sh

Own New
Grant·A
Feb 23, 26

Struthers Richard Scott KEY

President & CEO

$0

62.0K sh

Own +17%
Grant·A
Feb 23, 26

Betz Stephen F.

Chief Scientific Officer

$0

47.0K sh

Own New
Grant·A
Feb 23, 26

Betz Stephen F.

Chief Scientific Officer

$0

30.0K sh

Own +25%
Grant·A
Feb 23, 26

Schilke Tobin KEY

Chief Financial Officer

$0

50.0K sh

Own New
Grant·A
Feb 23, 26

Schilke Tobin KEY

Chief Financial Officer

$0

32.0K sh

Own +61%
Grant·A
Feb 23, 26

Kalofonos Isabel

Chief Commercial Officer

$0

55.0K sh

Own New
Grant·A
Feb 23, 26

Kalofonos Isabel

Chief Commercial Officer

$0

34.0K sh

Own +4077%
Grant·A
Feb 23, 26

Knight Jeff E.

Chief Operating Officer

$0

55.0K sh

Own New
Grant·A
Feb 23, 26

Knight Jeff E.

Chief Operating Officer

$0

34.0K sh

Own +39%
Exercise·M
Jan 5, 26

Kalofonos Isabel

Chief Commercial Officer · 10b5-1

$0

2.5K sh

Own +3%
Sell·S
Jan 5, 26

Kalofonos Isabel

Chief Commercial Officer · 10b5-1

$137.5K

2.5K sh · $55.00

Own -75%
Exercise·M
Jan 5, 26

Kalofonos Isabel

Chief Commercial Officer · 10b5-1

$101.5K

2.5K sh · $40.59

Own +300%
Exercise·M
Dec 26, 25

Betz Stephen F.

Chief Scientific Officer

$0

18.0K sh

Own +25%
Exercise·M
Dec 26, 25

Betz Stephen F.

Chief Scientific Officer

$34.4K

18.0K sh · $1.91

Own +18%
Exercise·M
Dec 18, 25

Struthers Richard Scott KEY

President & CEO

$0

28.4K sh

Own +12%
Exercise·M
Dec 18, 25

Struthers Richard Scott KEY

President & CEO

$0

16.3K sh

Own New
Exercise·M
Dec 18, 25

Struthers Richard Scott KEY

President & CEO

$151.7K

16.3K sh · $9.28

Own +5%
Exercise·M
Dec 18, 25

Struthers Richard Scott KEY

President & CEO

$434.2K

28.4K sh · $15.29

Own +8%
Exercise·M
Dec 1, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$0

5.0K sh

Own +8%
Exercise·M
Dec 1, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$84.5K

5.0K sh · $16.89

Own +7%
Sell·S
Dec 1, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$225.1K

5.0K sh · $45.02

Own -7%
Exercise·M
Nov 3, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$0

5.0K sh

Own +7%
Sell·S
Nov 3, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$4.3K

100 sh · $43.27

Own -0%
Sell·S
Nov 3, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$209.0K

4.9K sh · $42.65

Own -7%
Exercise·M
Nov 3, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$84.5K

5.0K sh · $16.89

Own +8%
Exercise·M
Oct 1, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$0

5.0K sh

Own +7%
Exercise·M
Oct 1, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$84.5K

5.0K sh · $16.89

Own +8%
Sell·S
Oct 1, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$209.1K

5.0K sh · $41.81

Own -7%
Exercise·M
Sep 26, 25

Fust Matthew K

Director · 10b5-1

$0

10.0K sh

Own New
Exercise·M
Sep 26, 25

Fust Matthew K

Director · 10b5-1

$19.1K

10.0K sh · $1.91

Own +35%
Sell·S
Sep 26, 25

Fust Matthew K

Director · 10b5-1

$716.0K

16.0K sh · $44.75

Own -41%
Sell·S
Sep 26, 25

Struthers Richard Scott KEY

President & CEO · 10b5-1

$180.0K

4.0K sh · $45.00

Own -4%
Exercise·M
Sep 2, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$0

5.0K sh

Own +6%
Sell·S
Sep 2, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$160.5K

5.0K sh · $32.10

Own -5%
Exercise·M
Sep 2, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$84.5K

5.0K sh · $16.89

Own +5%
Exercise·M
Aug 22, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$0

30.0K sh

Own +51%
Sell·S
Aug 22, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$912.9K

30.0K sh · $30.43

Own -31%
Exercise·M
Aug 22, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$506.7K

30.0K sh · $16.89

Own +45%
Sell·S
Aug 20, 25

Pizzuti Dana

Chief Med and Dev Officer · 10b5-1

$189.4K

6.5K sh · $29.18

Own -9%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Mar 16, 2026	Betz Stephen F. 10b5-1	Chief Scientific Officer	Sell S	4.2K	-3%	$37.77	$160.2K
Mar 16, 2026	Betz Stephen F. 10b5-1	Chief Scientific Officer	Sell S	6.4K	-4%	$37.11	$236.4K
Mar 16, 2026	Struthers Richard Scott KEY 10b5-1	President & CEO	Sell S	8.8K	-2%	$37.77	$331.8K
Mar 16, 2026	Struthers Richard Scott KEY 10b5-1	President & CEO	Sell S	13.2K	-3%	$37.11	$489.7K
Mar 16, 2026	Knight Jeff E. 10b5-1	Chief Operating Officer	Sell S	6.0K	-5%	$37.11	$220.8K
Mar 16, 2026	Knight Jeff E. 10b5-1	Chief Operating Officer	Sell S	4.0K	-3%	$37.77	$149.6K
Mar 12, 2026	Vivaldi Coelho Rogerio 10b5-1	Director	Sell S	523	-3%	$36.77	$19.2K
Mar 12, 2026	Vivaldi Coelho Rogerio 10b5-1	Director	Sell S	4.5K	-21%	$36.08	$161.5K
Mar 3, 2026	Okey Stephanie 10b5-1	Director	Sell S	3.0K	-18%	$39.67	$119.0K
Mar 3, 2026	Schilke Tobin KEY 10b5-1	Chief Financial Officer	Sell S	6.7K	-8%	$39.67	$266.3K
Feb 23, 2026	Struthers Richard Scott KEY	President & CEO	Grant A	228.0K	New	—	$0
Feb 23, 2026	Struthers Richard Scott KEY	President & CEO	Grant A	62.0K	+17%	—	$0
Feb 23, 2026	Betz Stephen F.	Chief Scientific Officer	Grant A	47.0K	New	—	$0
Feb 23, 2026	Betz Stephen F.	Chief Scientific Officer	Grant A	30.0K	+25%	—	$0
Feb 23, 2026	Schilke Tobin KEY	Chief Financial Officer	Grant A	50.0K	New	—	$0
Feb 23, 2026	Schilke Tobin KEY	Chief Financial Officer	Grant A	32.0K	+61%	—	$0
Feb 23, 2026	Kalofonos Isabel	Chief Commercial Officer	Grant A	55.0K	New	—	$0
Feb 23, 2026	Kalofonos Isabel	Chief Commercial Officer	Grant A	34.0K	+4077%	—	$0
Feb 23, 2026	Knight Jeff E.	Chief Operating Officer	Grant A	55.0K	New	—	$0
Feb 23, 2026	Knight Jeff E.	Chief Operating Officer	Grant A	34.0K	+39%	—	$0
Jan 5, 2026	Kalofonos Isabel 10b5-1	Chief Commercial Officer	Exercise M	2.5K	+3%	—	$0
Jan 5, 2026	Kalofonos Isabel 10b5-1	Chief Commercial Officer	Sell S	2.5K	-75%	$55.00	$137.5K
Jan 5, 2026	Kalofonos Isabel 10b5-1	Chief Commercial Officer	Exercise M	2.5K	+300%	$40.59	$101.5K
Dec 26, 2025	Betz Stephen F.	Chief Scientific Officer	Exercise M	18.0K	+25%	—	$0
Dec 26, 2025	Betz Stephen F.	Chief Scientific Officer	Exercise M	18.0K	+18%	$1.91	$34.4K
Dec 18, 2025	Struthers Richard Scott KEY	President & CEO	Exercise M	28.4K	+12%	—	$0
Dec 18, 2025	Struthers Richard Scott KEY	President & CEO	Exercise M	16.3K	New	—	$0
Dec 18, 2025	Struthers Richard Scott KEY	President & CEO	Exercise M	16.3K	+5%	$9.28	$151.7K
Dec 18, 2025	Struthers Richard Scott KEY	President & CEO	Exercise M	28.4K	+8%	$15.29	$434.2K
Dec 1, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	5.0K	+8%	—	$0
Dec 1, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	5.0K	+7%	$16.89	$84.5K
Dec 1, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Sell S	5.0K	-7%	$45.02	$225.1K
Nov 3, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	5.0K	+7%	—	$0
Nov 3, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Sell S	100	-0%	$43.27	$4.3K
Nov 3, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Sell S	4.9K	-7%	$42.65	$209.0K
Nov 3, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	5.0K	+8%	$16.89	$84.5K
Oct 1, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	5.0K	+7%	—	$0
Oct 1, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	5.0K	+8%	$16.89	$84.5K
Oct 1, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Sell S	5.0K	-7%	$41.81	$209.1K
Sep 26, 2025	Fust Matthew K 10b5-1	Director	Exercise M	10.0K	New	—	$0
Sep 26, 2025	Fust Matthew K 10b5-1	Director	Exercise M	10.0K	+35%	$1.91	$19.1K
Sep 26, 2025	Fust Matthew K 10b5-1	Director	Sell S	16.0K	-41%	$44.75	$716.0K
Sep 26, 2025	Struthers Richard Scott KEY 10b5-1	President & CEO	Sell S	4.0K	-4%	$45.00	$180.0K
Sep 2, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	5.0K	+6%	—	$0
Sep 2, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Sell S	5.0K	-5%	$32.10	$160.5K
Sep 2, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	5.0K	+5%	$16.89	$84.5K
Aug 22, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	30.0K	+51%	—	$0
Aug 22, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Sell S	30.0K	-31%	$30.43	$912.9K
Aug 22, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Exercise M	30.0K	+45%	$16.89	$506.7K
Aug 20, 2025	Pizzuti Dana 10b5-1	Chief Med and Dev Officer	Sell S	6.5K	-9%	$29.18	$189.4K

About CRNX insider trading

This page tracks insider transactions for Crinetics Pharmaceuticals, Inc. (CRNX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.